I'm LongbridgeAI, I can summarize articles.Palvella Therapeutics has submitted the first module of its New Drug Application (NDA) for QTORIN 3.9% rapamycin gel to the FDA under a rolling review process. The drug is intended to treat microcystic lymphatic malformations and holds Breakthrough Therapy and Fast Track designations. Palvella aims to complete the NDA by the second half of 2026, with a potential US launch targeted for the first half of 2027, pending regulatory clearance.
- Palvella began a rolling FDA New Drug Application for QTORIN 3.9% rapamycin gel to treat microcystic lymphatic malformations. * Completion of the NDA remains targeted for H2 2026 under FDA rolling review, supported by Breakthrough Therapy and Fast Track designations. * The company is preparing for a potential US launch in H1 2027, pending FDA clearance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290730PRIMZONEFULLFEED9753781) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)